Demand for shingles vaccination has surged across British pharmacies, with bookings at major chains more than doubling in recent years. While the vaccine’s primary purpose is preventing shingles, a painful rash caused by reactivation of the chickenpox virus, some of this increased uptake is motivated by emerging research suggesting a potential link between vaccination and reduced dementia risk.
Multiple scientific studies have found associations between shingles vaccination and lower dementia rates. Research from Stanford University examined a natural experiment in Wales where vaccination eligibility was determined by age cutoff, comparing dementia rates across thousands of people born on different sides of the threshold. The analysis found dementia rates were 8.5% lower over seven years in vaccine-eligible women, leading researchers to estimate the vaccine may reduce dementia risk by nearly 20%. Similar patterns have been reported in studies from Australia and Ontario, Canada. A more recent Oxford University study analyzing health records for over 200,000 vaccinated individuals found dementia cases were 17% lower in those receiving Shingrix, a newer vaccine, compared with those who received Zostavax. Women showed greater protection at 22% risk reduction compared with 13% for men.
The scientific hypothesis behind these associations centers on varicella zoster virus, which causes both chickenpox and shingles. After initial chickenpox infection, the virus remains dormant in nerve cells and can reactivate in later life when immune function declines, triggering shingles. Researchers theorize that in the brain, this virus may drive inflammation and contribute to accumulation of amyloid and tau proteins, which are hallmarks of Alzheimer’s disease. Vaccination could potentially interrupt this process. However, scientists emphasize these studies show correlation and association rather than definitive proof of causation.
The potential implications are significant given global dementia prevalence. Approximately 60 million people currently live with dementia worldwide, with projections exceeding 100 million by 2040. In England and Wales alone, dementia is expected to affect 1.7 million people by that year, with annual costs reaching £90 billion. Existing dementia treatments have shown limited effectiveness, making preventive interventions potentially valuable. Most people under 65 in Britain pay approximately £450 for the full shingles vaccination course, as it is not universally available free on the NHS for younger adults.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI